| abstract |
The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: —Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO 2 —R 1 ; —At the C terminal end of the peptide, Y is selected from OH, OR 1 , NH 2 , NHR 1 and NR 1 R 2 ; —R 1 and R 2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; —Pro* correspond to a Proline, an analogue or derivative thereof; —if X is H then Y is selected from OR 1 , NH 2 , NHR 1 and NR 1 R 2 , and if Y is OH then X is —CO— or —SO 2 —R 1 ; and the peptide hypoxanthine-Pro-Pro-Arg being excluded. The invention provides the use of the peptides of above formula I to stimulate the synthesis of the molecules constituting the dermal extracellular matrix, including collagen I and IV and elastin. A cosmetic treatment according to the invention includes anti-aging, anti-wrinkles, improving mechanical properties of the skin, firmness/tone/elasticity/suppleness/flexibility, increasing density and volume of the skin, restructuring effect, fighting stretch marks, improving skin barrier and/or skin hydration. |